26 May 2009
Nancy Faigen
nancy.faigen@informausa.com
Johnson & Johnson is to ask an arbitrator to dissolve its Remicade (infliximab) arthritis distribution agreement with
Schering-Plough in the wake of the proposed merger of Schering-Plough and
Merck & Co. If the agreement is terminated, J&J will regain full return of the rights to Remicade and...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Merck paying $950 million to settle US Vioxx criminal, civil charges
- US Capitol Capsule: Could another biosimilars fight be a brewin'?
- UCB opts for alliance as it picks Astellas as new Cimzia partner in Japan
- Nichi-Iko and Sanofi join forces for biosimilar infliximab in Japan
FEATURES
Other Informa Features
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
